ArticleBMC urology2025
Clinical and pathological analysis of primary well-differentiated neuroendocrine tumors in the kidney- a case series.
Article in BMC urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A case of renal primary neuroendocrine tumor (G3) in which 177Lu-PRRT was effective for disease control.Urology case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveTo investigate the clinicopathological characteristics and key diagnostic/therapeutic features of primary well-differentiated neuroendocrine tumors (WDNET) of the kidney.
methodsRetrospective analysis of 4 primary renal WDNET patients, including clinical features, pathological findings (Macroscopic and microscopic), immunophenotype, treatment, and outcomes.
resultsAll 4 patients were female (mean age: 55 ± 7.83 years), One patient occasionally experienced mild low back pain, one presented with "palpitations and fatigue," and the remaining two were incidentally found to have renal masses during abdominal ultrasound or CT examination.Macroscopic findings: Mean tumor diameter 6.1 ± 2.2 cm(range: 3.5-8.8 cm), solid gray-white/yellow cut surfaces. Microscopic findings: Characteristic trabecular/rosette-like patterns, uniform cells with "salt-and-pepper" chromatin, and rare mitotic activity. Immunohistochemistry(IHC): Positive for Synaptophysin (Syn), Chromogranin A(CgA), CD56, and Cytokeratin (CK); negative for renal markers; low Ki67 index. Two patients underwent radical nephrectomy, and two had partial nephrectomy. During follow-up (1-77 months), one patient developed liver metastasis at 50 months post-operation (stabilized with PRRT), while others showed no recurrence.
conclusionPrimary renal WDNET is clinically rare and lack specific manifestations, often misdiagnosed as renal cell carcinomas. Definitive diagnosis requires characteristic histomorphology combined with immunohistochemical markers. Currently, there is no unified grading system, and surgical resection remains the main treatment approach. However, prognostic factors and treatment responses remain unclear, necessitating further studies with larger case cohorts for comprehensive investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.